Skip to content
New: 100+ more US companies, including the big banks, plus insider trades from SEC filings

Health Care · NASDAQ: ALNY

Alnylam: how the business works

Alnylam makes RNAi medicines that switch off one harmful gene, mainly for ATTR amyloidosis, which damages the heart and nerves. Revenue was $3.71 billion in FY2025.

By · Checked against filings: . Editorial policy. Corrections

Follow Alnylam

Email me when Alnylam's page is updated after earnings.

We'll send a confirmation email first. See our privacy policy.

Alnylam Pharmaceuticals, Inc. · Cambridge, Massachusetts · Founded 2002

Updated for Q3 FY2026 · checked

Revenue, FY2025
$3.71B
Net income, FY2025
$313.7M
AMVUTTRA share of FY2025 revenue
62.3%
Revenue, Q3 FY2026
$1.46B
Full-time employees, end of 2025
About 2,500

For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

The short version

Alnylam in 5 points

  1. 1 · What it sells

    Alnylam sells RNAi medicines that silence one harmful gene, and AMVUTTRA, for ATTR amyloidosis, was 62.3% of its $3.71 billion FY2025 revenue.

    More: what it sells

  2. 2 · Who pays it

    Sales of Alnylam's four medicines were 80.4% of its FY2025 revenue, research partners such as Roche 14.9% and Novartis's Leqvio royalties 4.7%.

    More: who pays it

  3. 3 · What it keeps from $100

    Of every $100 that came in during FY2025, Alnylam kept $8.2 as net income after $34.5 on research and $31.6 on selling and admin; that $100 includes $116.7 million of interest and other income, and EBITDAOperating profit before wear-and-tear charges (depreciation and amortization). As a margin: per $100 of sales. from operations was $557 million.

    More: what it keeps from $100

  4. 4 · Where the operating profit comes from

    Alnylam reports one business segment and no profit by medicine; it turned profitable as revenue grew 103% from FY2023 to FY2025 while R&D grew 31%.

    More: where the operating profit comes from

  5. 5 · The one thing to watch

    AMVUTTRA brought in $1.13 billion in Q3 FY2026, and on Jul 30, 2026 Alnylam lowered its FY2026 TTR guidance to $4.2–4.5 billion.

    More: the one thing to watch

Sources: From Alnylam's FY2025 10-K, Q3 FY2026 10-Q and earnings releases · checked

01Where the money goes · FY2025

Where does $100 of Alnylam's money go?

Of every $100 that came in (revenue plus other income), this is where it went.

Alnylam · FY2025

Receipt for every $100

Where $100 of Alnylam's money went in FY2025
Research and development$34.5
Selling, general and admin$31.6
Making the medicines, incl. royalties paid$17.8
Interest on debt$6.6
Loss on buying back convertible notes$1.1
Income tax$0.2
Kept as net income$8.2
Total$100

Each line = amount ÷ total money in × 100. Lines may not add to exactly $100 because of rounding.

How this is worked out

Cityfort calculation from the FY2025 10-K. Of every $100 that came in during FY2025 (revenue of $3.71 billion plus $116.7 million of interest and other income, $3.83 billion in all): each line = line ÷ $3.83 billion × 100.

Save this receipt as an image

Embed this receipt or the key numbers

Paste this code into a blog or website to show the card you choose, with a link back to this page.

Each week: the next company due to report earnings, explained in 5 points.

No tips. Unsubscribe anytime.

We'll send a confirmation email. See our privacy policy.

02The business in one line

What does Alnylam do?

Alnylam sells four gene-silencing medicines, and partners pay for its research. Most of the money goes on research and selling. In FY2025, $8.2 of every $100 that came in was left as net income.

  • Sales of its four medicines were 80.4% of FY2025 revenue, research partners such as Roche 14.9%, and Novartis's royalties on Leqvio 4.7%.
  • Of every $100 that came in during FY2025, research took $34.5 and selling and admin $31.6 (Cityfort calculation from the FY2025 10-K).

03Who pays it

Who pays Alnylam?

  • Buyers of its medicines

    80.4%

    of revenue

    Customers that buy its four medicines; the largest, an unnamed distributor, was 45% of gross revenue. Net product revenue was $2.99 billion in FY2025.

  • Research partners

    14.9%

    of revenue

    Roche ($394.9 million in FY2025), Regeneron ($114.0 million) and others pay for rights and milestones.

  • Novartis (royalties)

    4.7%

    of revenue

    Pays royalties on its global Leqvio sales. Alnylam sold half of these royalties to a Blackstone affiliate in April 2020.

  • Buyers of its medicines80.4%
  • Research partners14.9%
  • Novartis (royalties)4.7%

Customer concentration

One distributor, unnamed in the FY2025 10-K and called Distributor A, was 45% of gross revenue in FY2025, up from 29% in FY2024 and 28% in FY2023. It also owed 45% of gross receivables at Dec 31, 2025.

Largest customer
45%

04How it makes money

How does Alnylam make money?

Sales grew faster than its research and selling costs, so losses turned into profit.

For years Alnylam spent more on research than it earned. From FY2023 to FY2025 revenue grew 103%, while R&D grew 31% and selling and admin 52% (Cityfort calculation from the FY2025 10-K). AMVUTTRA added $1.76 billion of that growth.

Net income per $100 of revenue

−$101.0$8.4

FY2021 to FY2025

  1. Research picks a gene to silence
  2. A medicine wins approval
  3. Sales and partner payments come in
  4. Revenue grows faster than costs
  5. Profit pays for more research

↺ Step 5 feeds back into step 1.

05Business segments · FY2025

Which businesses make up Alnylam?

  • AMVUTTRA

    62.3%

    TTR medicine for the nerve and heart forms of ATTR amyloidosis. Alnylam reports one business segment, so it gives no profit figure for any product.

    Revenue $2.3B ($2,314M)

  • ONPATTRO

    4.7%

    Older TTR medicine; sales were $354.5 million in FY2023, $252.9 million in FY2024 and $172.8 million in FY2025.

    Revenue $173M

  • GIVLAARI

    8.3%

    For acute hepatic porphyria.

    Revenue $309M

  • OXLUMO

    5.2%

    For primary hyperoxaluria type 1.

    Revenue $191M

  • Collaborations

    14.9%

    Partner payments; FY2025 includes a $300.0 million Roche milestone.

    Revenue $553M

  • Royalties

    4.7%

    Royalties on Novartis's Leqvio sales.

    Revenue $174M

How the mix changed

  • AMVUTTRA
  • ONPATTRO
  • GIVLAARI
  • OXLUMO
  • Collaborations
  • Royalties

Revenue by segment, FY2023 to FY2025.

US$

See the numbers
How the mix changed (US$)
YearAMVUTTRAONPATTROGIVLAARIOXLUMOCollaborationsRoyalties
FY2023$558M$355M$219M$110M$546M$40.6M
FY2024$971M$253M$256M$167M$510M$91.8M
FY2025$2.3B$173M$309M$191M$553M$174M

06The numbers · Consolidated · US$

How has Alnylam done?

Revenue

$3.7BFY2025

Revenue rose every year, from $844.3 million in FY2021 to $3.71 billion in FY2025, when AMVUTTRA brought in $2.31 billion.

US$

See the numbers
Revenue (US$)
PeriodRevenue (US$)
FY2021$844M
FY2022$1.0B
FY2023$1.8B
FY2024$2.2B
FY2025$3.7B
Q1 FY2024$494M
Q2 FY2024$660M
Q3 FY2024$501M
Q4 FY2024$593M
Q1 FY2025$594M
Q2 FY2025$774M
Q3 FY2025$1.2B
Q4 FY2025$1.1B
Q1 FY2026$1.2B
Q2 FY2026$1.3B
Q3 FY2026$1.5B

Net income

$314MFY2025

Alnylam lost money every year from FY2021 to FY2024; Q3 FY2026 net income of $2.17 billion includes a tax benefit of about $1.9 billion.

US$

See the numbers
Net income (US$)
PeriodNet income (US$)EPS ($)
FY2021−$853M−$7.20
FY2022−$1.1B−$9.30
FY2023−$440M−$3.52
FY2024−$278M−$2.18
FY2025$314M$2.33
Q1 FY2024−$65.9M−$0.52
Q2 FY2024−$16.9M−$0.13
Q3 FY2024−$112M−$0.87
Q4 FY2024−$83.8M−$0.65
Q1 FY2025−$18.3M−$0.14
Q2 FY2025−$72.2M−$0.55
Q3 FY2025$293M$2.14
Q4 FY2025$112M$0.82
Q1 FY2026$206M$1.51
Q2 FY2026$165M$1.21
Q3 FY2026$2.2B$15.72

Net income for every $100 of revenue

$8.4FY2025

Net income per $100 of revenue moved from a loss of $101.0 in FY2021 to a profit of $8.4 in FY2025.

Net margin: $ of net income per $100 of revenue

See the numbers
Net income for every $100 of revenue (Net margin: $ of net income per $100 of revenue)
YearNet marginEBITDA margin
FY2021−101.0%−78.3%
FY2022−109.0%−71.4%
FY2023−24.1%−12.5%
FY2024−12.4%−5.3%
FY20258.4%15.0%

Free cash flow

$465MFY2025

Free cash flow reached $465.4 million in FY2025, while stock-based compensation that year was $348.2 million, more than net income.

US$ · cash from operations minus spending on plants and equipment

See the numbers
Free cash flow (US$ · cash from operations minus spending on plants and equipment)
YearCash from operationsCapital spendingFree cash flow
FY2021−$642M$76.4M−$718M
FY2022−$541M$72.1M−$613M
FY2023$104M$62.2M$41.9M
FY2024−$8.3M$34.3M−$42.6M
FY2025$524M$58.7M$465M
See all yearly numbers
Alnylam annual financials, FY2021–FY2025, US$
YearRevenueEBITDANet incomeEPS ($)Operating cashCapexFree cash
FY2021$844M−$661M−$853M−$7.20−$642M$76.4M−$718M
FY2022$1.0B−$741M−$1.1B−$9.30−$541M$72.1M−$613M
FY2023$1.8B−$228M−$440M−$3.52$104M$62.2M$41.9M
FY2024$2.2B−$120M−$278M−$2.18−$8.3M$34.3M−$42.6M
FY2025$3.7B$557M$314M$2.33$524M$58.7M$465M

EBITDA here = operating income plus depreciation and amortization (from the cash flow statement). Fiscal years are the company's own: Fiscal year ends Dec 31 (the calendar year). Net income is the share belonging to the company's owners.

Learn: Fiscal years that don't end in December: Nvidia's FY2027 explained · Stock-based compensation and dilution: pay that becomes shares

07Who runs it

Who runs Alnylam, and did they deliver?

  • Yvonne L. Greenstreet, M.D.

    Chief Executive Officer · since 2022

    CEO since January 2022 and a director since October 2021; earlier President and Chief Operating Officer. In March 2026 she received a special award of performance share units that vest based on share-price goals through Dec 31, 2029.

  • Jeffrey V. Poulton

    Executive Vice President, Chief Financial Officer · since 2019

    CFO since August 2019.

  • Pushkal Garg, M.D.

    Executive Vice President, Chief Research and Development Officer · since 2025

    In this role since June 2025; Chief Medical Officer from January 2022.

  • Tolga Tanguler

    Executive Vice President, Chief Commercialization Officer · since 2021

    Joined as Chief Commercial Officer in January 2021. Leaves the role in December 2026, an 8-K filed Nov 5, 2026 says.

  • Bryan A. Supran

    Executive Vice President, Chief Legal Officer and Secretary · since 2025

    Joined on Sep 15, 2025.

What they said, and what happened

2 delivered · 1 withdrawn · 3 too early to tell

  1. Said on Oct 30, 2025

    FY2025 net product revenue of $2.95–3.05 billion.

    What happened

    Net product revenue was $2.99 billion in FY2025.

    Delivered
  2. Said on Oct 30, 2025

    FY2025 collaboration and royalty revenue of $650–750 million.

    What happened

    It was $727.4 million: $553.4 million from collaborations and $174.0 million of royalties.

    Delivered
  3. Said on Feb 12, 2026

    FY2026 TTR net product revenue of $4.4–4.7 billion.

    What happened

    Lowered to $4.2–4.5 billion on Jul 30, 2026.

    Withdrawn
  4. Said on Jul 30, 2026

    FY2026 net product revenue of $4.7–5.1 billion and $575–625 million from collaborations and royalties, reiterated on Oct 29, 2026.

    What happened

    Net product revenue for the first nine months of FY2026 was $3.50 billion (Cityfort calculation from the Q1 FY2026 to Q3 FY2026 earnings releases).

    Too early to tell
  5. Said on Oct 29, 2026

    Launch nucresiran in ATTR-CM by 2030, assuming positive data and regulatory approval.

    What happened

    Phase 3 TRITON-CM enrollment target raised to about 2,250 patients.

    Too early to tell
  6. Said on Nov 5, 2026

    Buy back about $500 million of stock by the end of 2026 and the rest of the $1.0 billion program in 2027.

    What happened

    Not yet reported.

    Too early to tell

08What could go wrong

What could go wrong for Alnylam?

  • Concentration

    One medicine brings in most of the money

    AMVUTTRA was 62.3% of FY2025 revenue and $1.13 billion of $1.46 billion in Q3 FY2026. ONPATTRO sales fell from $39.1 million in Q3 FY2025 to $19.6 million in Q3 FY2026.

    Watch AMVUTTRA sales each quarter against the FY2026 TTR guidance of $4.2–4.5 billion.

  • Competition

    Pills with lower list prices

    In the heart form, AMVUTTRA competes with Pfizer’s VYNDAQEL/VYNDAMAX and BridgeBio’s ATTRUBY, pills with lower US list prices. Other companies have heart-form drugs in Phase 3 trials.

    Watch Trial results from rivals and AMVUTTRA second-line demand.

  • Concentration

    One distributor is 45% of revenue

    An unnamed distributor was 45% of gross revenue in FY2025 and owed 45% of gross receivables at Dec 31, 2025.

    Watch The customer concentration note in the FY2026 10-K.

  • Legal

    Government subpoena on price reporting

    In October 2025 the US Attorney's Office for the District of Massachusetts subpoenaed documents on all four of Alnylam's own medicines. It covers government price reporting and fee and discount arrangements with distributors. Alnylam says it is producing records. The FY2025 10-K says no material loss contingencies were accrued at Dec 31, 2025.

    Watch Updates in the legal note of each 10-Q and 10-K.

  • Regulation

    US drug pricing rules

    The Q3 FY2026 10-Q names the Inflation Reduction Act, Medicare reimbursement changes and the 340B drug pricing program as possible pressures on demand and prices.

    Watch Medicare price rules and 340B changes named in filings.

  • Debt

    Royalty and funding obligations

    Beyond $1.01 billion of convertible notes, Alnylam carried $1.73 billion of liabilities at Sep 30, 2026 from selling future royalties and taking development funding. In Q3 FY2026, interest on them included about $58 million for the Leqvio royalty liability and $23 million for development funding.

    Watch Payments to the Blackstone affiliate and the 2027 notes due Sep 15, 2027.

  • Legal

    Patent challenges

    The Q3 FY2026 10-Q says generic makers can challenge listed patents, and a successful challenge could bring generic competition sooner.

    Watch Any patent challenge notices disclosed for AMVUTTRA.

09Supporters vs. critics

What do supporters and critics point to?

Facts each side points to. We don't say which side is right.

What supporters point to

  • Revenue rose every year, from $844.3 million in FY2021 to $3.71 billion in FY2025, and FY2025 was the first full-year profit in those five years.
  • AMVUTTRA sales were $1.13 billion in Q3 FY2026, up 65% from a year earlier, after its March 2025 US approval for the heart form.
  • Leqvio royalties were $94.7 million in Q3 FY2026, up from $46.2 million in Q3 FY2025.
  • Free cash flow was $465.4 million in FY2025, and cash and marketable securities of $3.59 billion exceeded the $1.01 billion of convertible notes at Sep 30, 2026.

What critics point to

  • AMVUTTRA was 62.3% of FY2025 revenue, and one unnamed distributor was 45% of gross revenue.
  • On Jul 30, 2026 Alnylam lowered its FY2026 TTR sales guidance to $4.2–4.5 billion from $4.4–4.7 billion.
  • In the heart form, AMVUTTRA competes with two pills that have lower US list prices, the Q3 FY2026 10-Q says.
  • Beyond its convertible notes, Alnylam carried $1.73 billion of liabilities at Sep 30, 2026 from selling future royalties and taking development funding.
  • Q3 FY2026 net income of $2.17 billion includes a tax benefit of about $1.9 billion, and stock-based compensation of $348.2 million in FY2025 was more than net income.

10What to watch next

What should you watch next at Alnylam?

Next event

Q4 FY2026 results

Date not announced yet.

  • AMVUTTRA sales against guidance

    AMVUTTRA brought in $1.13 billion in Q3 FY2026. On Oct 29, 2026 Alnylam reiterated FY2026 TTR guidance of $4.2–4.5 billion.

  • FDA decision on cemdisiran

    The Q3 FY2026 earnings release gives an FDA date in November 2026 for Regeneron's cemdisiran. If approved, Alnylam is eligible for royalties of up to 15% on its sales.

  • Share buyback

    The board authorized a $1.0 billion buyback on Nov 2, 2026. Alnylam said on Nov 5, 2026 it plans to buy about $500 million by the end of 2026.

  • Government subpoena

    A subpoena from the US Attorney's Office in Massachusetts in October 2025 asks for records on price reporting and distributor fees. Updates appear in the legal note of each 10-Q and 10-K.

11Key dates

What are the key dates for Alnylam?

Dates as stated in the filings. A date that no filing has given yet shows as not yet stated.
Key dates for Alnylam
EventDateSource
FDA target action date for cemdisiran (Regeneron)November 2026, as stated in the Q3 FY2026 earnings release.Not yet statedEarnings release for Q3 FY2026 (8-K Ex. 99.1)
Chief Commercialization Officer departsDecember 2026, as stated in the 8-K filed Nov 5, 2026.Not yet stated8-K Nov 5, 2026: Chief Commercialization Officer departure and $1.0 billion share repurchase program (Items 5.02/8.01)
1.00% convertible notes dueAbout $362.8 million of principal remained after the 2025 buybacks.Form 10-K for FY2025; 8-K Dec 11, 2025: repurchase of 1.00% notes due 2027 (Item 8.01)
0.00% convertible notes due$661.3 million of principal.Form 10-K for FY2025
Performance period of the CEO special award endsThe award vests based on share-price goals through this date.8-K Mar 4, 2026: special performance-based equity award to CEO (Item 5.02)
AMVUTTRA EU data exclusivity expiresTen-year EU market protection runs to Sep 16, 2032.Form 10-K for FY2025
Revolving credit line matures$500 million line, undrawn at Sep 30, 2026.Form 10-K for FY2025; Form 10-Q for Q3 FY2026

12Key facts

Key facts about Alnylam

What does Alnylam do?
Alnylam Pharmaceuticals makes RNAi medicines. Each one silences a single gene in the liver, and the body then makes less of a harmful protein. Alnylam sold four such medicines itself in FY2025: AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO.
How does Alnylam make money?
Alnylam earned $2.99 billion of its $3.71 billion FY2025 revenue from selling its own medicines, $553.4 million from research partners and $174.0 million of royalties on Novartis's Leqvio.
What is Alnylam's biggest medicine?
AMVUTTRA, for ATTR amyloidosis, brought in $2.31 billion, or 62.3% of Alnylam's FY2025 revenue. AMVUTTRA sales were $1.13 billion in Q3 FY2026, up 65% from Q3 FY2025.
Who are Alnylam's customers?
Sales of Alnylam's four medicines were 80.4% of its FY2025 revenue. One unnamed distributor was 45% of Alnylam's gross revenue in FY2025, up from 29% in FY2024.
How big is Alnylam?
Alnylam had $3.71 billion of revenue and $313.7 million of net income in FY2025, and about 2,500 full-time employees at Dec 31, 2025.
Is Alnylam profitable?
Alnylam lost money every year from FY2021 to FY2024 and earned $313.7 million in FY2025. Alnylam's Q3 FY2026 net income of $2.17 billion includes a tax benefit of about $1.9 billion.
Does Alnylam have debt?
At Sep 30, 2026 Alnylam had $3.59 billion of cash and marketable securities and convertible notes with a carrying value of $1.01 billion (Q3 FY2026 10-Q).
Who owns Alnylam?
Alnylam has one class of stock and no controlling holder. FMR LLC reported 12.7% in a Schedule 13GA filing by anyone who owns more than 5% of a company's shares and does not seek control. Learn more/A filed Nov 5, 2025, and Alnylam's directors and executive officers held less than 1% on Jan 31, 2026.

Terms on this page

Each explains the term in plain English, with the same number from other companies on Cityfort.

Go deeper

More detail from the same filings. Open any section.

13What it sells

13What it sells

What does Alnylam sell?

Alnylam makes RNAi medicines. Each one silences a single gene in the liver, so the body makes less of a harmful protein. It sells four such medicines itself and earns royalties and payments on others that partners sell.
  • AMVUTTRA (vutrisiran)

    Treats ATTR amyloidosis, where a liver protein called TTR builds up in nerves and the heart. Approved in the US for the nerve form in June 2022 and the heart form (ATTR-CM) in March 2025. Sales were $2.31 billion in FY2025.

  • ONPATTRO (patisiran)

    An older TTR medicine for the nerve form, the first RNAi medicine approved by the FDA. Sales fell 32% to $172.8 million in FY2025, with fewer patients on it.

  • GIVLAARI (givosiran)

    For acute hepatic porphyria, a rare liver disease. Sales were $308.5 million in FY2025, up 21%.

  • OXLUMO (lumasiran)

    For primary hyperoxaluria type 1, a rare disease. Sales were $191.4 million in FY2025, up 15%.

  • Leqvio and Qfitlia (sold by partners)

    Novartis sells Leqvio (inclisiran) and pays Alnylam royalties: $174.0 million in FY2025. Sanofi sells Qfitlia (fitusiran), approved by the FDA in March 2025 to prevent bleeding episodes.

  • Partner research deals

    Roche, Regeneron and others pay for rights to Alnylam drug candidates. Collaboration revenue was $553.4 million in FY2025, including a $300.0 million Roche milestone.

Think of it like this

An RNAi medicine works like a mute button for one gene: the cell stops reading the instructions for one harmful protein.

What it does

  • Does: Sells AMVUTTRA, ONPATTRO, GIVLAARI and OXLUMO itself in the US, Europe and other countries
  • Does: Earns royalties on Leqvio, which Novartis sells
  • Does: Gets upfront and milestone payments from partners such as Roche and Regeneron
  • Does: Makes medicines at its own plant in Cambridge, Massachusetts, in use since 2012

What it does not do

  • Does not: Does not sell Leqvio or Qfitlia itself: Novartis and Sanofi do
  • Does not: Does not report profit by product: it has one business segment
  • Does not: Has never paid a cash dividend
14How the money flows

14How the money flows · FY2025

How does money flow through Alnylam?

Money in

  • Medicine sales (net product revenue)$3.0B
  • Payments from research partners$553M
  • Royalties on Leqvio$174M
  • Interest and other income$117M

The company

Alnylam

$3.8B came in

Money out

  • Cost of making the medicines, incl. royalties it pays$682M
  • Research and development$1.3B
  • Selling, general and admin$1.2B
  • Interest on debt$253M
  • Loss on buying back convertible notes$42.5M
  • Income tax$9.4M
  • Net income$314M
  1. Alnylam took in $3.71 billion of revenue in FY2025, plus $116.7 million of interest and other income.
  2. Making the medicines, including royalties Alnylam pays on AMVUTTRA, cost $681.9 million.
  3. Research took $1.32 billion and selling and admin $1.21 billion.
  4. Interest on debt took $252.6 million, and buying back convertible notes cost another $42.5 million.
  5. After $9.4 million of tax, $313.7 million was left as net income, the only full-year profit from FY2021 to FY2025.
15What it needs to run

15What it needs to run

What does Alnylam need to run?

  • Ways to deliver RNAi into cells

    Its GalNAc and lipid nanoparticle methods deliver medicines to the liver. The FY2025 10-K describes a newer C16 method for the central nervous system and the eye.

  • Research spending

    R&D cost $1.32 billion in FY2025, more than a third of revenue, across more than 20 clinical programs.

  • Its own factory

    A plant in Cambridge, Massachusetts has made its medicines since 2012.

  • People

    About 2,500 full-time employees at Dec 31, 2025: about 1,945 in the US and 555 elsewhere.

16Where it sells

16Where it sells · FY2025

Where does Alnylam sell?

  • United States (medicine sales)69.2%
  • Europe (medicine sales)21.8%
  • Rest of world (medicine sales)9%
17Competitors and what protects it

17Competitors and what protects it

Who does Alnylam compete with?

Alnylam's biggest market is ATTR amyloidosis, where AMVUTTRA competes with two pills that have lower US list prices, the Q3 FY2026 10-Q says.
  • Pfizer

    NYSE: PFE

    Sells VYNDAQEL/VYNDAMAX (tafamidis), a pill for the heart form of ATTR amyloidosis, at a lower US list price than AMVUTTRA.

  • BridgeBio

    Sells ATTRUBY (acoramidis), another pill for the heart form, also at a lower US list price.

  • Ionis and AstraZeneca

    Sell WAINUA (eplontersen) for the nerve form. Its heart-form trial missed its main goal in August 2026, the Q3 FY2026 10-Q says.

  • Intellia and Regeneron

    Developing nexiguran ziclumeran for the heart form, in Phase 3 trials.

What protects the business

Each strength is scored 1 (weak) to 5 (strong) for the business, with the reason. It is not a rating of the share.

  • RNAi know-how4 of 5

    Six marketed RNAi medicines, two sold by partners, and more than 20 clinical programs at the time of the FY2025 10-K.

  • Partner income3 of 5

    Collaboration revenue and Leqvio royalties brought in $727.4 million in FY2025, about a fifth of revenue.

  • Exclusivity in Europe3 of 5

    AMVUTTRA's EU data exclusivity runs to Sep 16, 2030 and its market protection to Sep 16, 2032.

Weak spot

One medicine

AMVUTTRA was 62.3% of FY2025 revenue, and its two pill rivals in the heart form have lower US list prices.

18Where growth could come from

18Where growth could come from

Where could Alnylam's growth come from?

On Oct 29, 2026 Alnylam reiterated its FY2026 guidance: net product revenue of $4.7–5.1 billion (TTR medicines $4.2–4.5 billion, Rare $500–600 million) and $575–625 million from collaborations and royalties. On Jul 30, 2026 it had cut the TTR range from $4.4–4.7 billion.
Management statement, Oct 29, 2026. Reported as a statement, not our forecast.
  • AMVUTTRA in the heart form (ATTR-CM)

    Mixed

    AMVUTTRA total $1.13B in Q3 FY2026, up 65%

    Sales (nerve and heart forms; the company does not split them) rose from $685.3 million in Q3 FY2025. In July 2026 the CEO said second-line growth had normalized after early pent-up demand, and TTR guidance was lowered.

    Status: Mixed, partly on track.

  • AMVUTTRA outside the US

    Early

    Europe $130.7M in Q3 FY2026

    Up from $111.9 million a year earlier; rest of world was $91.0 million. The company cited heart-form launches in Japan, Germany and Italy.

    Status: Early, too early to judge.

  • Leqvio royalties

    Working

    $94.7M in Q3 FY2026

    Up from $46.2 million in Q3 FY2025, from higher Novartis sales volume and royalty rate, the company says.

    Status: Working, on track against what the company said.

  • Nucresiran (next TTR medicine)

    Early

    ~2,250-patient heart trial

    Two Phase 3 trials started in 2025. On Oct 29, 2026 the company said it still expects a heart-form launch by 2030, assuming positive data and approval.

    Status: Early, too early to judge.

  • Cemdisiran (Regeneron)

    New

    FDA date November 2026

    Regeneron is developing it for generalized myasthenia gravis. If approved, Alnylam is eligible for royalties of up to 15% on its sales.

    Status: New, recently announced.

  • Zilebesiran (Roche)

    Early

    $300.0M milestone, Sep 2025

    A blood-pressure candidate. Roche paid the milestone when the first patient was dosed in the ZENITH Phase 3 trial.

    Status: Early, too early to judge.

Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.

19The company's own measures (non-GAAP)

19The company's own measures · Q4 FY2025 to Q3 FY2026

What do Alnylam's own measures show?

Adjusted (non-GAAP) figures are Alnylam's own measures, shown next to the GAAP figure they start from. They are never added to GAAP numbers. The rest of the page uses GAAP.
  • Official (GAAP): Operating income, Q3 FY2026

    $346M

    Company's own measure: Non-GAAP operating income, Q3 FY2026

    $425M

    Alnylam leaves out stock-based compensationPay given as shares instead of cash, which spreads ownership more thinly. Learn more and losses related to its convertible debt. Its non-GAAPThe company's own "adjusted" numbers, not the official (GAAP) ones. Always read them next to the official figure. Learn more operating income was $476.2 million in Q3 FY2025, which included a $300.0 million Roche milestone.

  • Official (GAAP): Net income, Q3 FY2026

    $2.2B

    Company's own measure: Non-GAAP net income, Q3 FY2026

    $2.2B

    Both figures include a tax benefit of about $1.9 billion from releasing valuation allowances on US deferred tax assets. Non-GAAP net income was $437.8 million in Q3 FY2025.

  • Official (GAAP): Operating income, Q2 FY2026

    $231M

    Company's own measure: Non-GAAP operating income, Q2 FY2026

    $318M

    Same exclusions.

  • Official (GAAP): Operating income, Q1 FY2026

    $269M

    Company's own measure: Non-GAAP operating income, Q1 FY2026

    $339M

    Same exclusions.

  • Official (GAAP): Operating income, Q4 FY2025

    $132M

    Company's own measure: Non-GAAP operating income, Q4 FY2025

    $203M

    Same exclusions.

These are the company's own measures, defined by the company. They are not comparable across companies, and they are not added together. Each sits beside the nearest official (GAAP) figure.

Learn: Non-GAAP measures: what a company's "adjusted" numbers leave out · Stock-based compensation and dilution: pay that becomes shares

20Financial strength and debt

20Financial strength · Sep 30, 2026

How much debt does Alnylam have?

At Sep 30, 2026 Alnylam's cash and marketable securities of $3.59 billion were $2.57 billion more than the $1.01 billion carrying value of its convertible notes (Cityfort calculation from the Q3 FY2026 10-Q).
  • Total debt$1.0B
  • Cash and investments$3.6B
  • Net cash (cash minus debt)$2.6B
  • Net worth (shareholders' money)$3.6B
Debt to equity
0.28×
$ of debt for every $1 of shareholders' money
  • Debt here is the two convertible notes, bonds that can be swapped for shares. About $362.8 million of 1.00% notes is due Sep 15, 2027, and $661.3 million of 0.00% notes is due Sep 15, 2028.
  • Not counted as debt: $1.73 billion of liabilities from selling future royalties and taking development funding, mainly from a Blackstone affiliate, at Sep 30, 2026. The company repays them from Leqvio royalties and milestones.
  • Also not counted: operating lease liabilities of $249.4 million at Sep 30, 2026.
  • A $500 million revolving credit line, available to Sep 30, 2030 and secured by substantially all assets, had no borrowings at Sep 30, 2026.
  • Equity rose from $789.2 million at Dec 31, 2025 to $3.60 billion at Sep 30, 2026. Q3 FY2026 net income included a non-cash tax benefit of about $1.9 billion.
  • Debt to equity is the convertible notes ÷ stockholders’ equity of $3.60 billion (Cityfort calculation from the Q3 FY2026 10-Q).
21Who owns it

21Who owns it · ownership as of Jan 31, 2026

Who owns Alnylam?

Alnylam has one class of stock with one vote per share, and no holder controls it. Its 15 directors and executive officers held 1,139,927 shares on Jan 31, 2026, including 1,000,428 they could acquire within 60 days. The proxy shows this as less than 1% (0.9%, Cityfort calculation from the 2026 proxy statement). Holder rows have different dates and are never added.
Officers and directors (as a group), shares
0.9%
Share classes
Alnylam share classes: shares outstanding (millions) and votes per share
ClassShares (millions)Votes per shareHeld by% of shares% of votesTraded
Common stock (133,937,576 shares on Oct 23, 2026 (Q3 FY2026 10-Q cover). Alnylam has one class of common stock.)133.91–––Yes
Holders of 5% or more
Alnylam holders of 5% or more, from the proxy statement or later Schedule 13G filings; each row shows its own date
HolderSharesVotesAs ofSourceNote
FMR LLC12.7%–Nov 5, 2025S2816,834,095 shares, from a Schedule 13G/A filed Nov 5, 2025, as listed in the 2026 proxy statement.
Capital World Investors12.4%–Feb 9, 2024S2816,398,889 shares, from a Schedule 13G/A filed Feb 9, 2024. This is old data.
The Vanguard Group9.8%–Apr 7, 2025S2813,056,605 shares, from a Schedule 13G/A filed Apr 7, 2025.
BlackRock, Inc.6.4%–Jan 26, 2024S288,546,557 shares, from a Schedule 13G/A filed Jan 26, 2024. This is old data.
Capital Research Global Investors5.3%–Feb 13, 2025S286,968,513 shares, from a Schedule 13G filed Feb 13, 2025.

From the company's proxy statement (DEF 14A), later Schedule 13G filings and the share counts on its latest annual or quarterly report. Each holder row shows the date of its own filing.

Learn: How to read a proxy statement (DEF 14A): Nvidia's 2026 proxy · Form 4 insider filings: who files, the codes and the footnotes

22What it does with profit

22What it does with profit

What does Alnylam do with its profit?

Alnylam has never paid a cash dividend and says it has no present intention to pay one (FY2025 10-K). On Nov 2, 2026 its board authorized buying back up to $1.0 billion of stock. The company said it expects to buy about $500 million by the end of 2026 and the rest in 2027 (8-K filed Nov 5, 2026).
  • Money raised · Sep 15, 2022

    Issued $1,035.0 million of 1.00% convertible senior notes due 2027.

    $1.0B

  • Money raised · Sep 12, 2025

    Issued $661.3 million of 0.00% convertible senior notes due 2028, and used cash to buy back $637.8 million of the 2027 notes.

    $661M

23Governance signals

23Governance signals

What do Alnylam's governance filings show?

Auditor
PricewaterhouseCoopers LLP, since 2003
Auditor changes
None in the period covered
Audit qualifications
None reported
Related-party dealings
The 2026 proxy statement describes Alnylam's policy: the chief legal officer or the CFO reviews any proposed related person transaction, and the audit committee approves or ratifies it.
Credit rating
Not checked for this page

Flags to know about

  • regulatory · Oct 29, 2026

    Subpoena on government price reporting

    In October 2025 Alnylam received a subpoena from the US Attorney's Office for the District of Massachusetts. It seeks documents on government price reporting for AMVUTTRA, ONPATTRO, OXLUMO and GIVLAARI, including fee and discount arrangements with distributors. Alnylam says it has produced records and continues to engage with the office.

  • other · Nov 5, 2026

    Chief Commercialization Officer leaving

    Tolga Tanguler will leave his role as Executive Vice President, Chief Commercialization Officer in December 2026, an 8-K filed Nov 5, 2026 says.

  • other · Feb 12, 2026

    Accounting change restated 2025 quarters

    Alnylam adopted ASU 2025-07 in 2025 and adjusted earlier 2025 quarters to match. It added $271.5 million to stockholders’ equity through the accumulated deficit; FY2024 was not recast.

24How it got here

24How it got here

How did Alnylam get here?

  1. 2002

    Milestone

    Founded to turn RNAi into medicines

    Alnylam was founded in 2002 to make medicines from the discovery of RNA interference.

  2. 2018

    Milestone

    First medicine approved

    Patisiran (ONPATTRO), the first RNAi medicine approved by the FDA, was approved in the EU in August 2018.

  3. 2020

    Business-model change

    Sold half of the Leqvio royalties

    A Blackstone affiliate paid $1.0 billion in April 2020 for 50% of Leqvio royalties, plus up to $150 million of development funding.

  4. 2020

    Milestone

    Two rare-disease medicines approved in Europe

    Givosiran (GIVLAARI) in March 2020 and lumasiran (OXLUMO) in November 2020.

  5. 2022

    Milestone

    AMVUTTRA approved for the nerve form

    The FDA approved vutrisiran for nerve damage from hereditary ATTR amyloidosis in June 2022.

  6. 2023

    Milestone

    Roche deal for zilebesiran

    Roche joined the blood-pressure program in July 2023 and paid a $300.0 million milestone in September 2025.

  7. 2025

    Business-model change

    AMVUTTRA approved for the heart form

    The FDA approved it for ATTR-CM in March 2025. AMVUTTRA sales rose 138% to $2.31 billion in FY2025.

  8. 2025

    Milestone

    First full-year profit in the five years shown

    Net income was $313.7 million in FY2025, after a $278.2 million loss in FY2024.

  9. 2026

    Milestone

    $1.0 billion buyback authorized

    The board authorized the program on Nov 2, 2026.

25Sources and changes

Where every number on this page comes from

Sources (24 documents)
  1. S1Form 10-Q for Q3 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Oct 29, 2026
  2. S2Form 10-Q for Q2 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Jul 30, 2026
  3. S3Form 10-K for FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Feb 12, 2026
  4. S4Form 10-Q for Q3 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Oct 30, 2025
  5. S5Form 10-Q for Q2 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Jul 31, 2025
  6. S6Form 10-Q for Q1 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · May 1, 2025
  7. S7Form 10-K for FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Feb 13, 2025
  8. S8Form 10-Q for Q3 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Oct 31, 2024
  9. S9Form 10-Q for Q2 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Aug 1, 2024
  10. S10Form 10-Q for Q1 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · May 2, 2024
  11. S11Form 10-K for FY2023 · SEC EDGAR · Tier 1: company or exchange filing · Feb 15, 2024
  12. S12Form 10-K for FY2022 · SEC EDGAR · Tier 1: company or exchange filing · Feb 23, 2023
  13. S13Form 10-K for FY2021 · SEC EDGAR · Tier 1: company or exchange filing · Feb 10, 2022
  14. S14Form 10-Q for Q1 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Apr 30, 2026
  15. S15Earnings release for Q1 FY2026 (8-K Ex. 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Apr 30, 2026
  16. S18Earnings release for Q2 FY2026 (8-K Ex. 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Jul 30, 2026
  17. S198-K Sep 12, 2025: 0.00% Convertible Senior Notes due 2028 closing, $575.0M (Items 1.01/2.03/3.02) · SEC EDGAR · Tier 1: company or exchange filing · Sep 12, 2025
  18. S20Earnings release for Q3 FY2026 (8-K Ex. 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Oct 29, 2026
  19. S218-K Nov 5, 2026: Chief Commercialization Officer departure and $1.0 billion share repurchase program (Items 5.02/8.01) · SEC EDGAR · Tier 1: company or exchange filing · Nov 5, 2026
  20. S23Earnings release for Q3 FY2025 (8-K Ex. 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Oct 30, 2025
  21. S258-K Dec 11, 2025: repurchase of 1.00% notes due 2027 (Item 8.01) · SEC EDGAR · Tier 1: company or exchange filing · Dec 11, 2025
  22. S26Earnings release for Q4 and full year FY2025 (8-K Ex. 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Feb 12, 2026
  23. S278-K Mar 4, 2026: special performance-based equity award to CEO (Item 5.02) · SEC EDGAR · Tier 1: company or exchange filing · Mar 4, 2026
  24. S28Proxy statement (DEF 14A) for the 2026 annual meeting · SEC EDGAR · Tier 1: company or exchange filing · Apr 6, 2026
Changes to this page (v1 · Nov 20, 2026)
  1. v1 · Nov 20, 2026First version. (first version)

Numbers come only from tier 1 and tier 2 sources. Read how we research.

Disclaimer

For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.

Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a registered investment adviser or other qualified professional.

Cityfort, its owners and contributors may or may not hold securities of companies covered. Cityfort is not paid by any company it covers. Content is not an offer or solicitation to buy or sell any security, including in any initial public offering.

Read the positions policy
Read the full disclaimer

Cityfort publishes general educational content that explains how listed companies work. Cityfort is not registered with the US Securities and Exchange Commission or any state securities regulator as an investment adviser, and is not a broker-dealer or a member of FINRA. Cityfort does not provide investment, tax or legal advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security. Nothing on the site is tailored to any person's circumstances.

All information is taken from publicly available sources, mainly company filings with the SEC, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.

Statements by company management, including forward-looking statements and guidance, are reported as the company's statements, with their date and source; they are not our forecasts. Adjusted (non-GAAP) figures are the company's own measures and are shown next to the official (GAAP) figures.